Aegerion Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 92   

Articles published

AEGR 20.19 -14.02 (-40.98%)
price chart
Aegerion Pharmaceuticals (AEGR) Stock Downgraded Today at Jefferies
"We rate AEGERION PHARMACEUTICALS INC (AEGR) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared ...
Aegerion Falls On Disappointing Earnings  Bidness ETC
Midday Losers From October 31: Aegerion Pharmaceuticals, Bottomline ...  Benzinga
Related articles »  
Aegerion Pharmaceuticals (AEGR) Is Today's Dead Cat Bounce Stock
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States.
Aegerion Pharmaceuticals to Announce Third-Quarter 2014 Financial Results on ...  MarketWatch
Notable Movers- Aegerion Pharmaceuticals, (NASDAQ:AEGR), Dean Foods Co ...  Techsonian (press release)
Related articles »  
Aegerion Pharmaceuticals Inc. (AEGR) Set A New Low After Guidance Lowered
Aegerion Pharmaceuticals Inc. (AEGR: Quote) reported third quarter adjusted EPS of $0.12 after the close Thursday, compared to the loss of $0.17 in the previous year.
Buzz Stocks: Citigroup Inc, Wal-Mart Stores, Inc., and Aegerion ...
The market is ready to rally this morning, after the Bank of Japan (BoJ) announced a fresh stimulus plan overnight. Among specific equities to watch today are financial firm Citigroup Inc (NYSE:C), retailer Wal-Mart Stores, Inc. (NYSE:WMT), and ...
Morning Buzz: Imperva Inc. (IMPV), Sarepta Therapeutics (SRPT), Aegerion ...
Shares of Aegerion Pharmaceuticals, Inc. (AEGR) are down nearly 32% in early trading, after the company reported fiscal Q3 revenue that missed consensus.
Trending The Red Line: Aegerion Pharmaceuticals, Inc. (AEGR), Banco ...
There is no adequate room for optimism in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), according to the analysts at Jefferies.
Will Aegerion (AEGR) Disappoint This Earnings Season?
Teva will report third-quarter results on Oct 30 before market opens. Vertex Pharmaceuticals Inc. (VRTX - Analyst Report) has an Earnings ESP of +28.07% and holds a Zacks Rank #3 (Hold).
Will Aegerion (AEGR) Disappoint This Earnings Season? - Analyst Blog  Nasdaq
Related articles »  
Aegerion Pharmaceuticals Plunges to New 52-Week Low
Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR) reported its third-quarter results Thursday after the market close as -$0.12 in earnings per share and $43.7 million in revenue, against Thomson Reuters consensus estimates of -$0.14 in earnings per share ...
Aegerion Pharmaceuticals Downgraded by Needham & Company LLC to "Hold ...
Aegerion Pharmaceuticals (NASDAQ:AEGR) last posted its quarterly earnings results on Thursday, October 30th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.06. The company had ...
Related articles »  
Aegerion Pharmaceuticals Rating Lowered to Hold at Deutsche Bank (AEGR)
Aegerion Pharmaceuticals, Inc. logo Aegerion Pharmaceuticals (NASDAQ:AEGR) was downgraded by Deutsche Bank from a �buy� rating to a �hold� rating in a research note issued on Friday, TheFlyOnTheWall.